Skip to content

Our Story

Sunshine Labs is Canada’s first Safer Supply company. We produce and deliver products to the global market.

Based in Canada on the west coast of British Columbia, our facility and location were selected to allow the benefits of scalability. Oryx Biomed Ltd holds the Dealer’s License and is a wholly owned subsidiary of Sunshine Earth Labs Ltd.

We are establishing international partnerships to provide Controlled Substances and Psychedelics under the guidelines of the CDSA. We advocate for the responsible use of these substances while championing wider availability for therapeutic and medicinal purposes.

The Solution

The Solution is Sunshine Labs three tier response to helping solve the overdose crisis. We’re innovating how we respond to critical overdose situations as well as providing safe medications for those with substance use disorders as well as those who are ready for new treatment options to address the underlying causes of addiction.

Our License

Our Dealer’s License includes several controlled substances in amounts that allow for provision of Safer Supply. Health Canada allows us to possess, produce, assemble, sell and transport these restricted substances which include: Psilocybin, MDMA, Coca Leaf and Cocaine, DAM (heroin), Morphine and Opium, Psilocin, Methamphetamine, and Dexamphetamine. We do not sell controlled substances to the general public.

Featured in over 200 media outlets globally
The Team


Donovan Edwards

Chief Executive Officer

Donovan Edwards has extensive experience working in the international cannabis industry. He has had dialogue with various governments on the future of drug policy and trade relations. He has also consulted on cannabis regulatory issues, including legalization, and standard operating procedures on four continents. Donovan has more than 20 years of experience working under Health Canada’s MMAR & MMPR.

Dr. Stan deVlaming, MD

Chief Medical Officer

Dr. DeVlaming has over 25 years’ experience treating addictions, with 10 years spent serving as head of Addiction Medicine at St. Paul’s Hospital. He has served 8 years as Medical Director for Vancouver Coastal Health’s Inner-City Clinics. He is also extensively published and presented in the areas of HIV, Hepatitis C and Addiction. Currently, Dr. Devlaming is Clinical Assistant Professor at the University of British Columbia Faculty of Medicine, Associate Chief Medical Information Officer for Vancouver Coastal Health Community and a practicing physician in a Downtown Vancouver East side Medical Clinic

Andrew Pike, JD

Chief Legal Officer

Andrew Pike has a B.A. from the University of Victoria, and is a Juris Doctor from the University of Windsor. He is founder and former Senior Director of Opportunitas Aequa – registered charity using soccer as a peace building tool. Pike was called to the bar in British Columbia and is practicing corporate and commercial matters as well as real estate conveyancing.

N.M. Ramzan

Chief Operations Officer

Nameer Ramzan is a serial entrepreneur who has helped create multi-million dollar business ventures in North America and globally. He has built production and cultivation facilities as well as successfully opened retail dispensaries. Ramzan’s international ventures also included a founding partner of Yom Chai, an International Clinical Trial company.

Amber Wood, R.Ac, FMP

Chief Creative Officer, Director of Wellness

Innovation in medicine and governance is Amber’s passion. Her clinical practice applies evidence-based research to support patients. Content marketing and education has allowed her to reach a global audience. Leadership and capacity building in diverse communities around issues of mental health inform the work she does today. Generating resilience through peer support and harm reduction are foundational to her approach. Amber graduated with high honours and is licensed in British Columbia.

Mark Epping-Jordan, PhD

Chief Science Officer

Mark Epping-Jordan is a neuroscientist with over 30 years experience in behavioural pharmacology, addiction research and drug development. He was a co-founder and the Chief Scientific Officer of Addex Therapeutics, a Swiss pharmaceutical company. In that role, he was responsible for directing all preclinical behavioural testing, numerous multinational collaborations and was the behavioural lead for co-development projects with large pharma partners including Janssen and Merck. He was integrally involved in raising more than $100 million in venture capital and in the company’s IPO on the Swiss Stock Exchange, which raised over $110 million. Dr. Epping-Jordan is the author of numerous scientific publications including in high-impact journals such as Nature and Nature Neuroscience, and is an inventor on multiple patents.


Board of Advisors

Duncan Penn


Duncan Penn is a 4 time New York Times Bestselling Author, Executive Producer, and an early Investor in Lyft, SpaceX, Tesla, Superette, and Loan Pal. He has lectured at TEDx, Harvard Law, Facebook, Amazon, Microsoft and over 100+ North American Colleges and Universities. Penn has been featured on The Today Show, The Oprah Winfrey Show, Fortune.

Drummond Munro


Drummond Munro is an investor, Brand Adviser and Chief Brand Officer of Superette, an award winning cannabis retailer and lifestyle brand. He has spent the last ten years working with some of North America’s top retail brands on strategy, design, real estate selection, and international expansion strategies. These include: Tokyo Smoke, Herschel, Kit + Ace, Nike to name a few and has been featured in Forbes, NYT, BrandingMag, Globe and Mail and many others.

Most recently, Munro helped build the retail program at Tokyo Smoke, and led its expansion efforts until its sale to Canopy Growth in 2018 for $500 million.

Suzanne Wood


Suzanne Wood has over 30 years’ experience in financial and corporate sectors, specializing in small cap management and regulatory compliance assistance. She has worked with Revenue Canada’s Business Audit Division, as well as serving as Senior Executive for both private and publicly listed companies on exchanges including the TSX-V, TSX, CSE, AMEX, NASDAQ, and the OTCBB.

Dr. Linnell Malinson Edwards, PhD, MSc


Dr. Linnell Malinson Edwards has been a 35 year Research Scientist for the Government of Canada (Retired), Adjunct Professor at Dalhousie University (Retired), and Board of Governors member for the University of Prince Edward Island (Retired). Dr. Edwards is a current Member of the Farm Practices Review Board and Environmental Advisory Council for the Government of Prince Edward Island.

Dr. Edwards has an extensive background and expertise in Agronomy (Crops and Soils) with focus on practical application of field and laboratory scientific research. He has national and International private sector experience performing Environmental Impact Assessments, Industrial Land Reclamation, and Agricultural Diversification Planning in Alberta, Quebec, Nigeria, Mozambique, Burkina Faso, Lebanon, Algeria, and St. Lucia.

The Lab

Our laboratory is legally authorized to research the medicinal uses of restricted substances, and traditional whole plants, as well as the benefits of their pharmaceutical extracts. Sunshine Labs operates under Health Canada’s Controlled Drugs and Substances Act (CDSA). We are committed to the safe, effective, and sustainable use of plant medicines.

Sunshine Labs will offer c/euGMP medicinal products to the international market. We are well positioned to meet the future demands of this growing marketplace. Located in Canada on the West Coast of British Columbia, the property has been chosen to allow all of the benefits of scalability.